[Business Wire] – Gilead Sciences, Inc. today announced that the European Commission has granted marketing authorization for Vitekta™ tablets, an integrase inhibitor for the treatment of HIV-1 infection in adults without known mutations associated with resistance to elvitegravir.
Read more on … [visit site to read more]
- AbbVie Inc. (NYSE:ABBV) ~ AbbVie’s hepatitis C treatment helps 96 pct of patients in trial
- Gilead Sciences Inc. (NASDAQ:GILD) | Gilead to Present Data on Oncology Pipeline at American Society of Hematology Annual Meeting
- Market Update on Gilead Sciences Inc. (NASDAQ:GILD) – Gilead Sciences Expections Down
